{
    "name": "pasireotide",
    "comment": "Rx",
    "other_names": [
        "Signifor",
        "Signifor LAR"
    ],
    "classes": [
        "Somatostatin Analogs"
    ],
    "source": "https://reference.medscape.com/drug/signifor-signifor-lar-pasireotide-999801",
    "pregnancy": {
        "common": [
            "Limited data with pasireotide in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage",
            "In embryofetal development studies in rabbits, findings indicating a developmental delay were observed with SC administration of pasireotide during organogenesis at doses less than the exposure in humans at the highest recommended dose; maternal toxicity was not observed at this dose",
            "Discuss the potential for unintended pregnancy with premenopausal women as the therapeutic benefits of a reduction in growth hormone (GH) levels and normalization of insulin-like growth factor (IGF-1) in acromegalic females treated with pasireotide may lead to improved fertility"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There is no information available on the presence of pasireotide in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production",
            "Studies show that pasireotide administered subcutaneously passes into the milk of lactating rats; however, due to species-specific differences in lactation physiology, animal data may not reliably predict drug levels in human milk"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Suppresses ACTH, which may lead to decreased cortisol and potential hypocortisolism",
                "Can cause increased blood glucose levels, which are sometimes severe; patients with poor baseline glycemic control are at higher risk of developing severe hyperglycemia; access fasting blood glucose and HgA1c before initiating and monitor blood glucose the first 3 months after initiating an for 4-6 weeks after a dose increase",
                "May cause bradycardia and QT prolongation; obtain baseline and periodic ECG, and potassium and magnesium levels; correct/supplement potassium and /or magnesium if clinically warranted",
                "Increased liver enzymes may occur and may require dose interruption and reduction",
                "Cholelithiasis reported; perform gallbladder ultrasound at baseline and at 6- to 12-months; if complications of cholelithiasis suspected, discontinue therapy and treat appropriately",
                "Monitor for pituitary hormone deficiency (eg, TSH/free T4, GH/IGF-1)"
            ],
            "specific": [
                {
                    "type": "Hyperglycemia",
                    "description": [
                        "Blood glucose elevations have reported with therapy",
                        "In clinical study, patients developed pre-diabetes and diabetes; nearly all patients in the study, including those with normal glucose status at baseline, pre-diabetes, and diabetes, developed worsening glycemia in first two weeks of treatment",
                        "Cushing’s disease patients with poor glycemic control (HbA1c > 8%) may be at a higher risk of developing severe hyperglycemia and associated complications, eg, ketoacidosis",
                        "Assess patient’s glycemic status prior to starting treatment; in patients with uncontrolled diabetes mellitus, optimize anti-diabetic therapy prior to initiation of treatment",
                        "Glycemic monitoring should be done every week for first two to three months and periodically thereafter, as well as over first two to four weeks after any dose increase",
                        "If hyperglycemia develops, initiate or adjust anti-diabetic treatment per standard of care; if uncontrolled hyperglycemia persists despite appropriate treatment, reduce dose or discontinue therapy and perform glycemic monitoring according to clinical practice",
                        "Patients who were initiated on anti-diabetic treatment as a result of therapy require closer monitoring after discontinuation of treatment, especially if anti-diabetic therapy has a risk of causing hypoglycemia",
                        "Postmarketing cases of ketoacidosis reported in patients with history of diabetes and in patients without history of diabetes",
                        "Assess FPG and HbA1c prior to starting treatment; in patients with poorly controlled diabetes mellitus, optimize anti-diabetic treatment before initiating therapy",
                        "Patients receiving anti-diabetic treatment may require more frequent blood glucose monitoring and dose adjustment to their anti-diabetic drug therapy to mitigate risk of hypoglycemia after discontinuing therapy",
                        "Patients who present with signs and symptoms consistent with severe metabolic acidosis should be assessed for ketoacidosis regardless of diabetes history",
                        "If ketoacidosis is suspected, discontinue therapy and promptly evaluate and treat patient"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dronedarone",
            "description": {
                "common": "dronedarone and pasireotide both increase  QTc interval. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "pimozide",
            "description": {
                "common": "pimozide and pasireotide both increase  QTc interval. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "thioridazine",
            "description": {
                "common": "thioridazine and pasireotide both increase  QTc interval. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "adagrasib",
            "description": {
                "common": "adagrasib, pasireotide.\nEither increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amisulpride",
            "description": {
                "common": "amisulpride and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "anagrelide",
            "description": {
                "common": "anagrelide and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "artemether",
            "description": {
                "common": "artemether and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine",
            "description": {
                "common": "buprenorphine and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine buccal",
            "description": {
                "common": "buprenorphine buccal and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine subdermal implant",
            "description": {
                "common": "buprenorphine subdermal implant and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine transdermal",
            "description": {
                "common": "buprenorphine transdermal and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine, long-acting injection",
            "description": {
                "common": "buprenorphine, long-acting injection and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ceritinib",
            "description": {
                "common": "ceritinib and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "desflurane",
            "description": {
                "common": "desflurane and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "entrectinib",
            "description": {
                "common": "pasireotide and entrectinib both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eribulin",
            "description": {
                "common": "eribulin and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glasdegib",
            "description": {
                "common": "pasireotide and glasdegib both increase  QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydroxychloroquine sulfate",
            "description": {
                "common": "hydroxychloroquine sulfate and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "inotuzumab",
            "description": {
                "common": "inotuzumab and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "isoflurane",
            "description": {
                "common": "isoflurane and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ivosidenib",
            "description": {
                "common": "ivosidenib and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lefamulin",
            "description": {
                "common": "lefamulin and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "macimorelin",
            "description": {
                "common": "macimorelin and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mobocertinib",
            "description": {
                "common": "mobocertinib and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, reduce mobocertinib dose and monitor QTc interval more frequently."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "oxaliplatin and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "panobinostat",
            "description": {
                "common": "pasireotide and panobinostat both increase  QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pitolisant",
            "description": {
                "common": "pasireotide and pitolisant both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ponesimod",
            "description": {
                "common": "ponesimod, pasireotide.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Consult cardiologist if considering treatment. Coadministration of ponesimod with drugs that decrease HR may have additive effects on decreasing HR and should generally not be initiated in these patients."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ribociclib",
            "description": {
                "common": "ribociclib increases toxicity of pasireotide by QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sevoflurane",
            "description": {
                "common": "sevoflurane and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "tacrolimus and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tetrabenazine",
            "description": {
                "common": "tetrabenazine and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "toremifene",
            "description": {
                "common": "toremifene and pasireotide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "umeclidinium bromide/vilanterol inhaled",
            "description": {
                "common": "pasireotide increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vilanterol/fluticasone furoate inhaled",
            "description": {
                "common": "pasireotide increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "albuterol",
            "description": {
                "common": "albuterol and pasireotide both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alfuzosin",
            "description": {
                "common": "alfuzosin and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiodarone",
            "description": {
                "common": "amiodarone and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "amitriptyline and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amoxapine",
            "description": {
                "common": "amoxapine and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "apomorphine",
            "description": {
                "common": "apomorphine and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "arformoterol",
            "description": {
                "common": "arformoterol and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "aripiprazole and pasireotide both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "arsenic trioxide",
            "description": {
                "common": "arsenic trioxide and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "artemether/lumefantrine",
            "description": {
                "common": "artemether/lumefantrine and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine",
            "description": {
                "common": "asenapine and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine transdermal",
            "description": {
                "common": "asenapine transdermal and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atomoxetine",
            "description": {
                "common": "atomoxetine and pasireotide both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azithromycin",
            "description": {
                "common": "azithromycin and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bedaquiline",
            "description": {
                "common": "pasireotide and bedaquiline both increase  QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bromocriptine",
            "description": {
                "common": "pasireotide increases levels of bromocriptine by decreasing metabolism. Use Caution/Monitor. Somatropin may increase CYP450 enzymes and, therefore, suppression of growth hormone secretion by somatostatin analogs including pasireotide may decrease the metabolic clearance of compounds metabolized by CYP450 enzymes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "chlorpromazine and pasireotide both decrease  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ciprofloxacin",
            "description": {
                "common": "ciprofloxacin and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "citalopram",
            "description": {
                "common": "citalopram and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "clarithromycin and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clomipramine",
            "description": {
                "common": "clomipramine and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clozapine",
            "description": {
                "common": "clozapine and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "copper CU 64 dotatate",
            "description": {
                "common": "pasireotide decreases effects of copper CU 64 dotatate by receptor binding competition. Modify Therapy/Monitor Closely. Somatostatin analogs competitively bind to the same somatostatin receptors as CU 64 dotatate and may affect imaging. Image patients just prior to dosing with somatostatin analogs. Washout period of 28 days recommended for patients on long-acting somatostatin analogs before imaging; whereas, 2 days washout recommended for short-acting somatostatin analogs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "crizotinib",
            "description": {
                "common": "crizotinib and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "pasireotide decreases levels of cyclosporine by unspecified interaction mechanism. Use Caution/Monitor. Coadministration may decrease bioavailability of oral cyclosporine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dasatinib",
            "description": {
                "common": "dasatinib and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "degarelix",
            "description": {
                "common": "degarelix and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desipramine",
            "description": {
                "common": "desipramine and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deutetrabenazine",
            "description": {
                "common": "deutetrabenazine and pasireotide both increase  QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and pasireotide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "disopyramide",
            "description": {
                "common": "disopyramide and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dofetilide",
            "description": {
                "common": "dofetilide and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dolasetron",
            "description": {
                "common": "dolasetron and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "donepezil",
            "description": {
                "common": "donepezil and pasireotide both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxepin",
            "description": {
                "common": "doxepin and pasireotide both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "droperidol",
            "description": {
                "common": "droperidol and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz and pasireotide both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eliglustat",
            "description": {
                "common": "eliglustat and pasireotide both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "erythromycin base and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "erythromycin ethylsuccinate and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "erythromycin lactobionate and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "erythromycin stearate and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "escitalopram",
            "description": {
                "common": "escitalopram and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ezogabine",
            "description": {
                "common": "ezogabine and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fingolimod",
            "description": {
                "common": "fingolimod and pasireotide both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flecainide",
            "description": {
                "common": "flecainide and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluconazole",
            "description": {
                "common": "fluconazole and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "fluoxetine and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "fluphenazine and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "formoterol",
            "description": {
                "common": "formoterol and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "foscarnet",
            "description": {
                "common": "foscarnet and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fostemsavir",
            "description": {
                "common": "pasireotide and fostemsavir both increase  QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gallium Ga 68 dotatate",
            "description": {
                "common": "pasireotide decreases effects of gallium Ga 68 dotatate by receptor binding competition. Modify Therapy/Monitor Closely. Somatostatin analogs competitively bind to the same somatostatin receptors as Ga 68 dotatate and may affect imaging. Image patients with Ga 68 dotatate PET just prior to dosing with long-acting somatostatin analogs. Short-acting somatostatin analogs can be used up to 24 hr before imaging with Ga 68 dotatate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gallium Ga 68 dotatoc",
            "description": {
                "common": "pasireotide decreases effects of gallium Ga 68 dotatoc by receptor binding competition. Modify Therapy/Monitor Closely. Somatostatin analogs competitively bind to the same somatostatin receptors as Ga 68 dotatoc and may affect imaging. Image patients with Ga 68 dotatoc PET just prior to dosing with long-acting somatostatin analogs. Short-acting somatostatin analogs can be used up to 24 hr before imaging with Ga 68 dotatoc."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gemifloxacin",
            "description": {
                "common": "gemifloxacin and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gemtuzumab",
            "description": {
                "common": "pasireotide and gemtuzumab both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gilteritinib",
            "description": {
                "common": "gilteritinib and pasireotide both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "goserelin",
            "description": {
                "common": "goserelin increases toxicity of pasireotide by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "granisetron",
            "description": {
                "common": "granisetron and pasireotide both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haloperidol",
            "description": {
                "common": "haloperidol and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "histrelin",
            "description": {
                "common": "histrelin increases toxicity of pasireotide by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydroxyzine",
            "description": {
                "common": "hydroxyzine and pasireotide both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibutilide",
            "description": {
                "common": "ibutilide and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "iloperidone and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indapamide",
            "description": {
                "common": "indapamide and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin aspart",
            "description": {
                "common": "pasireotide increases effects of insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and somatostatin analogs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin aspart protamine/insulin aspart",
            "description": {
                "common": "pasireotide increases effects of insulin aspart protamine/insulin aspart by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and somatostatin analogs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec",
            "description": {
                "common": "pasireotide, insulin degludec.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec/insulin aspart",
            "description": {
                "common": "pasireotide, insulin degludec/insulin aspart.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin detemir",
            "description": {
                "common": "pasireotide increases effects of insulin detemir by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and somatostatin analogs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glargine",
            "description": {
                "common": "pasireotide increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and somatostatin analogs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glulisine",
            "description": {
                "common": "pasireotide increases effects of insulin glulisine by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and somatostatin analogs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin inhaled",
            "description": {
                "common": "pasireotide, insulin inhaled.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin isophane human/insulin regular human",
            "description": {
                "common": "pasireotide increases effects of insulin isophane human/insulin regular human by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and somatostatin analogs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin lispro",
            "description": {
                "common": "pasireotide increases effects of insulin lispro by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and somatostatin analogs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin lispro protamine/insulin lispro",
            "description": {
                "common": "pasireotide increases effects of insulin lispro protamine/insulin lispro by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and somatostatin analogs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin NPH",
            "description": {
                "common": "pasireotide increases effects of insulin NPH by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and somatostatin analogs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin regular human",
            "description": {
                "common": "pasireotide increases effects of insulin regular human by unspecified interaction mechanism. Use Caution/Monitor. Concomitant use of insulin and somatostatin analogs may require insulin dosage adjustment and increased glucose monitoring."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isradipine",
            "description": {
                "common": "isradipine and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "itraconazole",
            "description": {
                "common": "itraconazole and pasireotide both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lapatinib",
            "description": {
                "common": "lapatinib and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenvatinib",
            "description": {
                "common": "pasireotide and lenvatinib both increase  QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "leuprolide",
            "description": {
                "common": "leuprolide increases toxicity of pasireotide by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levofloxacin",
            "description": {
                "common": "levofloxacin and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lithium",
            "description": {
                "common": "lithium and pasireotide both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lopinavir",
            "description": {
                "common": "lopinavir and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lumefantrine",
            "description": {
                "common": "lumefantrine and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lutetium Lu 177-dota-tate",
            "description": {
                "common": "pasireotide decreases effects of lutetium Lu 177-dota-tate by receptor binding competition. Modify Therapy/Monitor Closely. Somatostatin analogs competitively bind to the same somatostatin receptors as lutetium Lu 177-dota-tate and may affect its efficacy. Discontinue long-acting somatostatin analogs at least 4 weeks and short-acting octreotide at least 24 hr prior to each lutetium Lu 177-dota-tate dose. Administer short- and long-acting octreotide during treatment as recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maprotiline",
            "description": {
                "common": "maprotiline and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mefloquine",
            "description": {
                "common": "mefloquine and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metformin",
            "description": {
                "common": "pasireotide decreases effects of metformin by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methadone",
            "description": {
                "common": "methadone and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mifepristone",
            "description": {
                "common": "mifepristone and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mirtazapine",
            "description": {
                "common": "mirtazapine and pasireotide both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moxifloxacin",
            "description": {
                "common": "moxifloxacin and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nilotinib",
            "description": {
                "common": "nilotinib and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nortriptyline",
            "description": {
                "common": "nortriptyline and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "octreotide",
            "description": {
                "common": "octreotide and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofloxacin",
            "description": {
                "common": "ofloxacin and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olanzapine",
            "description": {
                "common": "olanzapine and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ondansetron",
            "description": {
                "common": "ondansetron and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "osilodrostat",
            "description": {
                "common": "osilodrostat and pasireotide both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "osimertinib",
            "description": {
                "common": "osimertinib and pasireotide both increase  QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "oxaliplatin will increase the level or effect of pasireotide by  Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ozanimod",
            "description": {
                "common": "ozanimod and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paliperidone",
            "description": {
                "common": "paliperidone and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pazopanib",
            "description": {
                "common": "pazopanib and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentamidine",
            "description": {
                "common": "pentamidine and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perphenazine",
            "description": {
                "common": "perphenazine and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "posaconazole",
            "description": {
                "common": "posaconazole and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primaquine",
            "description": {
                "common": "primaquine and pasireotide both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "procainamide",
            "description": {
                "common": "procainamide and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propafenone",
            "description": {
                "common": "propafenone and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "protriptyline",
            "description": {
                "common": "protriptyline and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quetiapine",
            "description": {
                "common": "quetiapine and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinidine",
            "description": {
                "common": "quinidine and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinine",
            "description": {
                "common": "quinine and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ranolazine",
            "description": {
                "common": "ranolazine and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "risperidone",
            "description": {
                "common": "risperidone and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "romidepsin",
            "description": {
                "common": "romidepsin and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "selpercatinib",
            "description": {
                "common": "selpercatinib increases toxicity of pasireotide by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sertraline",
            "description": {
                "common": "sertraline and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "solifenacin",
            "description": {
                "common": "solifenacin and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sorafenib",
            "description": {
                "common": "sorafenib and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sotalol",
            "description": {
                "common": "sotalol and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sunitinib",
            "description": {
                "common": "sunitinib and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "telavancin",
            "description": {
                "common": "telavancin and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thiothixene",
            "description": {
                "common": "thiothixene and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triclabendazole",
            "description": {
                "common": "triclabendazole and pasireotide both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimipramine",
            "description": {
                "common": "trimipramine and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triptorelin",
            "description": {
                "common": "triptorelin increases toxicity of pasireotide by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valbenazine",
            "description": {
                "common": "valbenazine and pasireotide both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vandetanib",
            "description": {
                "common": "vandetanib and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vardenafil",
            "description": {
                "common": "vardenafil and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vemurafenib",
            "description": {
                "common": "vemurafenib and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin, pasireotide.\nEither increases effects of the other by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voriconazole",
            "description": {
                "common": "voriconazole and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vorinostat",
            "description": {
                "common": "vorinostat and pasireotide both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ziprasidone",
            "description": {
                "common": "ziprasidone and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chloroquine",
            "description": {
                "common": "chloroquine increases toxicity of pasireotide by QTc interval. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Diarrhea",
            "percent": "58-59"
        },
        {
            "name": "Nausea",
            "percent": "46-58"
        },
        {
            "name": "Hyperglycemia",
            "percent": "38-43"
        },
        {
            "name": "Cholelithiasis",
            "percent": "30"
        },
        {
            "name": "Headache",
            "percent": "28-29"
        },
        {
            "name": "Abdominal pain",
            "percent": "23-25"
        },
        {
            "name": "Fatigue",
            "percent": "15-24"
        },
        {
            "name": "Diabetes mellitus",
            "percent": "16-20"
        },
        {
            "name": "Injection site reactions",
            "percent": "17-18"
        },
        {
            "name": "Asthenia",
            "percent": "6-16"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "12-14"
        },
        {
            "name": "Increased alanine aminotransferase",
            "percent": "8-13"
        },
        {
            "name": "ALT",
            "percent": "1"
        },
        {
            "name": "Increased A",
            "percent": "10-12"
        },
        {
            "name": "c",
            "percent": "39"
        },
        {
            "name": "Diarrhea",
            "percent": "29"
        },
        {
            "name": "Hyperglycemia",
            "percent": "26"
        },
        {
            "name": "Diabetes mellitus",
            "percent": "26"
        },
        {
            "name": "Cholelithiasis",
            "percent": "19"
        },
        {
            "name": "Headache",
            "percent": "18"
        },
        {
            "name": "Alopecia",
            "percent": "18"
        },
        {
            "name": "Abdominal pain",
            "percent": "16"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "14"
        },
        {
            "name": "Nausea",
            "percent": "13-16"
        },
        {
            "name": "Increased creatinine phosphokinase",
            "percent": "4-15"
        },
        {
            "name": "Hypoglycemia",
            "percent": "4-14"
        },
        {
            "name": "Insomnia",
            "percent": "12"
        },
        {
            "name": "Abdominal distension",
            "percent": "9-12"
        },
        {
            "name": "Increased gamma",
            "percent": "8-12"
        },
        {
            "name": "glutamyl transferase",
            "percent": "2"
        },
        {
            "name": "Upper abdominal pain",
            "percent": "6-12"
        },
        {
            "name": "Type",
            "percent": "5-12"
        },
        {
            "name": "diabetes mellitus",
            "percent": "6-11"
        },
        {
            "name": "Myalgia",
            "percent": "6-11"
        },
        {
            "name": "Anxiety",
            "percent": "10-11"
        },
        {
            "name": "Influenza",
            "percent": "9-11"
        },
        {
            "name": "Peripheral edema",
            "percent": "9-11"
        },
        {
            "name": "Decreased appetite",
            "percent": "10"
        },
        {
            "name": "Hypercholesterolemia",
            "percent": "9-10"
        },
        {
            "name": "Hypertension",
            "percent": "5-10"
        },
        {
            "name": "Dizziness",
            "percent": "4-10"
        },
        {
            "name": "Arthralgia",
            "percent": "3-10"
        },
        {
            "name": "Vomiting",
            "percent": "7-9"
        },
        {
            "name": "Sinus bradycardia",
            "percent": "6-9"
        },
        {
            "name": "Pruritus",
            "percent": "5-9"
        },
        {
            "name": "ncreased lipase",
            "percent": "6-8"
        },
        {
            "name": "Constipation",
            "percent": "5-8"
        },
        {
            "name": "Hypotension",
            "percent": "5-7"
        },
        {
            "name": "Back pain",
            "percent": "5-7"
        },
        {
            "name": "Hypokalemia",
            "percent": "4-7"
        },
        {
            "name": "Pain in extremity",
            "percent": "4-7"
        },
        {
            "name": "Increased AST",
            "percent": "6"
        },
        {
            "name": "Increased blood glucose",
            "percent": "6"
        },
        {
            "name": "Dry skin",
            "percent": "5-8"
        },
        {
            "name": "Prolonged QT interval",
            "percent": "5-6"
        },
        {
            "name": "Vertigo",
            "percent": "5-6"
        },
        {
            "name": "Abdominal distension",
            "percent": "6"
        },
        {
            "name": "Adrenal insufficiency",
            "percent": "6"
        },
        {
            "name": "ncreased AST",
            "percent": "4"
        },
        {
            "name": "Increased blood glucose",
            "percent": "2"
        },
        {
            "name": "Anemia",
            "percent": "2"
        },
        {
            "name": "Increased amylase",
            "percent": "10"
        },
        {
            "name": "Prolonged PTT",
            "percent": "10"
        },
        {
            "name": "Arthralgia",
            "percent": "10"
        },
        {
            "name": "Fatigue",
            "percent": "8"
        },
        {
            "name": "Dizziness",
            "percent": "8"
        },
        {
            "name": "Increased blood glucose",
            "percent": "8"
        },
        {
            "name": "Influenza",
            "percent": "8"
        },
        {
            "name": "Vomiting",
            "percent": "8"
        },
        {
            "name": "Hypertension",
            "percent": "8"
        },
        {
            "name": "Increased ALT",
            "percent": "7"
        },
        {
            "name": "Back pain",
            "percent": "7"
        },
        {
            "name": "Pain in extremity",
            "percent": "7"
        },
        {
            "name": "Upper respiratory infection",
            "percent": "6"
        },
        {
            "name": "Injection site reactions",
            "percent": "6"
        },
        {
            "name": "Increased glycosylated hemoglobin",
            "percent": "6"
        },
        {
            "name": "Upper abdominal pain",
            "percent": "5"
        },
        {
            "name": "Increased aspartate aminotransferase",
            "percent": "5"
        },
        {
            "name": "AST",
            "percent": "5"
        },
        {
            "name": "Decreased weight",
            "percent": null
        },
        {
            "name": "Cough",
            "percent": null
        },
        {
            "name": "Hypoglycemia",
            "percent": null
        },
        {
            "name": "Ketoacidosis",
            "percent": null
        }
    ]
}